CVS Health Corp. on Dec. 12 launched a precision medicine strategy to help improve outcomes and lower overall costs for cancer patients.

The program called Transform Oncology Care uses genomic testing results at the point-of-prescribing to help determine the best treatment plan for patients based on their clinical and genetic profiles.

CVS Health is offering the plan in partnership with healthcare technology startup Tempus Labs Inc., which offers genomic sequencing and biological modeling services.

The drug retailer said the broad-panel gene sequencing tests help identify a patient's genomic variants and the therapeutic options specific to their molecular and clinical profile. The results of these tests also make it possible for the patient to be part of local clinic trials under Tempus' proprietary platform, facilitating broader access to experimental therapies, CVS Health said.

The program includes company nurse-led care management that is integrated with the payor's existing programs. Payors can also opt for value-based contracts that employ provider networks to improve care and reduce costs, the company said.

CVS Health's Aetna is rolling out the program in 12 states. The company said the program is also available to other health plans.